PPT-ASCO 2019 NSCLC - PARP & Chemotherapy

ASCO 2019 NSCLC PARP amp Chemotherapy REF Study Study details Line Drug BiomarkerSubgroup N Primary endpoint Secondary endpoints 1 arapatxBodyatcPr marL50800 marR50800 marT50800 marB50800 horzOverflowoverflowalnL w4445asolidFillasrgbClr val000000asolidFillamiter lim400000alnLalnR w4445asolidFillasrgbClr val000000asolidFillamiter lim400000alnRalnTasolidFillasrgbClr val000000asolidFillamiter lim400000alnTalnB w4445asolidFillasrgbClr val000000asolidFillamiter lim400000alnBanoFillatcPratcatcatxBodyabodyPralstStyleapapPr algnl defTabSz457200adefRPr sz1800apPrararPrasym typefaceHelvetica NeuearPr. Ranee Mehra, MD. Fox Chase Cancer Center. Philadelphia, PA. Disclosures. Consulting – Novartis, Bristol Myers Squib. Spouse is employee of GSK. Acknowledgment: J. Weiss. Ras-Raf-MEK-ERK1/2 MAP . kinase. Renato G. Martins, MD, MPH. Medical Director, Thoracic/Head and Neck; General Oncology and Hematology. Seattle Cancer Care Alliance. July 28, 2015. 11:30 am – 12:30 pm, EST. ICLIO e-Course 02. Objectives. MD. The Evolving Treatment Landscape in NSCLC: Congress Updates. Outline of Talk. Provide a brief overview of current advances in the treatment of NSCLC. EGFR-targeted agents . ALK-EML4 targeted agents . Jared Weiss, MD . Assistant . Professor of Medicine . Division . of Hematology and Oncology . University . of North Carolina School of Medicine . Attending Physician. UNC . Lineberger. Comprehensive Cancer . and Opportunities. This program will include a discussion . of off-label treatment and investigational agents not approved by the FDA for use . in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.. The Coming Paradigm Shift. Faculty. Suresh S. Ramalingam, MD. Professor of Hematology/Oncology . Director, Lung . Cancer Program . Winship Cancer Institute. Emory University. Atlanta, . Georgia. Program Goals. Dr Tan . Jiunn. Liang. Clinical Specialist (Respiratory Medicine). Department of Medicine. Universiti. Malaya Medical Centre. Disclaimer. This program is provided as a service to the medical profession and represents the opinions of the speakers, not necessarily those of Merck or MSD or its affiliates. Niraparib. and . Temozolomide. in Patients with Previously Treated, incurable Ewing Sarcoma . Co-Principal Investigators: . Sandra . Strauss, MD, PhD. University College London. Rashmi. . Chugh. , MD. PARP Inhibitors: What Do We know?. PARP Inhibitors: What Do We Know? (cont). PARP Inhibitors: What Don't We Know ?. SOLO-1: Study Rationale and Design. [a]. Primary Endpoint and Other . R. esults. Time to Second Progression or Death (. The Role of Antiangiogenic Agents in the Changing Treatment Paradigm of NSCLC: Expert Perspectives Moderator Solange Peters, MD, PhD Chair, Medical Oncology Department of Oncology Centre Hospitalier Universitaire Vaudois (CHUV) Lisa McCluskey, MD. Gynecologic Oncologist. June 16, 2015. Compass Oncology . in partnership with . Ovarian . Cancer Alliance of Oregon & SW . Washington. What. is Ovarian Cancer. ?. The most common type of Ovarian Cancer that starts from . Kamil Konopka. Department of Oncology, University Hospital in Cracow. Lung cancer epidemiology. Most common malignancy worldwide. 14% of all new cancers are lung cancers. Lung cancer (NSCLC&SCLC) is the second most common cancer in both men and women (excluding skin cancers). Osp. . Pertini-S.Eugenio-CTO. Therapeutic. . approach. . to. . HER 2 . breast. . cancer. . in . metastatic. . setting. Lisa Carey, SABCS 2018. La malattia HER2 positiva: . Trastuzumab. Key Phase III HER2 Positive MBC Trials. Professor Rachel Butler. The genomic complexity of advanced NSCLC. Jordan et al. Cancer Discovery (2017). >50% NSCLC now have actionable variant. Treatment algorithm. NHSE: National Genomic Test Directory.